Tositumomab/iodine-131 tositumomab (Bexxar) is a radioimmunotherapeutic agent in development for patients with low-grade or transformed non-Hodgkin’s lymphoma (NHL). This analysis focuses
J. M. Vose
Advertisement
Articles by J. M. Vose
Iodine-131 tositumomab (Bexxar) is a new radioimmunotherapy in development for the treatment of patients with low-grade or transformed low-grade non-Hodgkin’s lymphoma. The data from five phase I-III studies, which enrolled patients with low-
Advertisement
Latest Updated Articles
- Iodine-131 Tositumomab for Patients With Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma: Complete Response Data
Published: March 1st 2001 | Updated:
- Iodine I 131 Tositumomab for Patients With Follicular Non-Hodgkin’s Lymphoma (NHL): Overall Clinical Trial Experience by Histology
Published: March 1st 2000 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
3 Things You Should Know About Single-Agent ADCs in TNBC Treatment
2
Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group
3
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
4
Response Rates Show Promise in Phase 1 Trial Involving ASCT in Metastatic PDAC
5
